Exploring the FAP-Targeted Therapeutics for Adrenocortical Carcinoma: Choosing the Right Track

Area of Science:

• Oncology
• Radiochemistry
• Molecular Imaging

Background:

• Adrenocortical carcinoma (ACC) is a rare and aggressive cancer with poor prognosis.
• Effective systemic treatments for metastatic or recurrent ACC are lacking, necessitating novel therapeutic strategies.
• Targeting the tumor microenvironment, specifically fibroblast activation protein (FAP)-expressing cancer-associated fibroblasts, offers a promising avenue for ACC theranostics.

Purpose of the Study:

• To evaluate novel fibroblast activation protein inhibitors (FAPis) as theranostic probes for adrenocortical carcinoma.
• To assess the potential of DOTA.SA.FAPi (SA.FAPi), FAPi46, and FAP2286 for targeting FAP in ACC.

Main Methods:

• In silico evaluation and/or preclinical studies of three FAP inhibitors: DOTA.SA.FAPi, FAPi46, and FAP2286.
• Assessment of FAP-targeting capabilities and theranostic potential in the context of adrenocortical carcinoma.

Main Results:

• The study investigated the theranostic potential of three distinct FAP inhibitors.
• Preliminary data suggests these molecules may effectively target FAP in the context of ACC.

Conclusions:

• Fibroblast activation protein inhibitors represent a promising class of molecules for adrenocortical carcinoma theranostics.
• Further investigation into DOTA.SA.FAPi, FAPi46, and FAP2286 could lead to new targeted therapies for ACC.